Results 101 to 110 of about 7,739 (166)

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure

Drug, Healthcare and Patient Safety, 2014
Irmina Urbanek, Krzysztof Kaczmarek, Iwona Cygankiewicz, Pawel PtaszynskiDepartment of Electrocardiology, Chair of Cardiology and Cardiosurgery, Medical University, Lodz, PolandAbstract: Heart rate is not only a major risk marker in heart failure but ...
Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P   +3 more
doaj  

Comparison of endothelial function in patients with Stage I-II arterial hypertension and stable angina, receiving various bradycardic agents and perindopril

Кардиоваскулярная терапия и профилактика, 1970
Aim. To compare endothelial function in patients with Stage I-II arterial hypertension (AH) and Functional Class (FC) II stable angina, receiving either beta-adrenoblocker (metoprolol tartrate) or If channel inhibitor (ivabradine), combined with ...
L. L. Kirichenko, A. N. Golosova, S. V. Gatsura, A. P. Korolev, K. V. Ovsyannikov, P. V. Struchkov   +5 more
doaj  

Investigation of Bicarphen and Ivabradine crystalline forms

, 2017
Bikarfēna un ivabradīna kristālisko formu izpēte. Borisova A., zinātniskais vadītājs Dr. ķīm., prof. Andris Actiņš. Maģistra darbs, 60 lpp., 19 attēli, 7 tabulas, 46 literatūras avoti, 2 pielikumi.
Borisova, Anastasija
core  

Propranolol and Ivabradine Are Equally Effective in POTS But Not Equipoise in Real Life. [PDF]

JACC Adv
Goff A, Nguyen C, Hunyor I, O'Sullivan J, Wilcox I.   +4 more
europepmc   +1 more source

PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients

Background: Ivabradine reduces heart rate by inhibiting the “funny current” expressed on the sinoatrial node and improves mortality and morbidity in patients with systolic heart failure and sinus tachycardia.
Toshihide Izumida, Koichiro Kinugawa, Riona Yamamoto, Teruhiko Imamura, Naoya Kataoka   +4 more
core   +1 more source

Ivabradine in a Neonate With Severe Hypertrophic Cardiomyopathy. [PDF]

JACC Case Rep
Karikari YS, Baxter G, Martinez HR, Ryan K, Guerrier K.   +4 more
europepmc   +1 more source

Ivabradine in Postural Orthostatic Tachycardia Syndrome. Is That All We Need? [PDF]

Arq Bras Cardiol
Brasil HN, Cunha BL, de Mendonça ATB, Pereira FTM, Rocha EA.   +4 more
europepmc   +1 more source

Impact of Once-Daily Ivabradine on Average Resting Heart Rate in Patients With Reduced Ejection Fraction With Systolic Dysfunction: A Multicenter, Post-marketing Observational Study. [PDF]

Cureus
Mullasari A, Abdullakutty J, Suryavanshi S, Gadkari MA, Aggrawal RK, Sable A, Sawant P.   +6 more
europepmc   +1 more source

Role of ivabradine for anthracycline-induced cardiotoxicity: a meta-analysis. [PDF]

Cardiooncology
Umar M, Ali A, Guha A, Baig MMA, Khattak F, Addison D.   +5 more
europepmc   +1 more source

A sustainable spectrofluorimetric method for ivabradine quantification based on erythrosin B quenching with quantum mechanical modeling and Box-Behnken design optimization. [PDF]

RSC Adv
Alqahtani AS, Abduljabbar MH, Alnemari RM, Althobaiti MM, Aldawsari MF, Al-Mutairi AA, Serag A, Almalki AH.   +7 more
europepmc   +1 more source